A recent study reveals that patients who come off new slimming jabs like Wegovy and Mounjaro may regain reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a leading health publication demonstrates that while overweight individuals can lose a large proportion of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing such drugs must be informed of the potential of quick weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment mass in about 18 months.
Analyzing Treatments
The analysis, which reviewed 37 of trials involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers note that individuals who shed pounds through dieting typically have a more gradual creep back—around 100 grams monthly—post-intervention.
The Reason for the Quick Regain
Nutrition scientists propose the mode of action of the injections is key to understanding the heightened weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Long-term administration of GLP-1 levels far above than normal might result in the body to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making binge eating far more likely."
A Chronic Disease?
Medical guidelines recommend the injections for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, considering the significant potential of relapse, the therapy might need to be long-term.
This perspective is echoed by drug manufacturers, who note that the results "highlight the chronic nature of obesity," similar to managing diseases like hypertension.
User Testimonies
Users who have discontinued the medication explain a intense return of hunger.
"I experienced something that goes on and you're instantly extremely hungry," said one woman.
This challenge is exacerbated if users have not established permanent lifestyle or habit modifications during treatment.
Widespread Use
Figures show that a significant number of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Use is more common among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, researchers stress that while GLP-1 drugs are effective agents for shedding pounds, they are not a standalone solution and maintained weight loss relies on combined behavioural management.
